Cargando…

The Anti-Aggregative Potential of Resolvin E1 on Human Platelets

Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Szymańska, Patrycja, Luzak, Bogusława, Miłowska, Katarzyna, Golański, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385542/
https://www.ncbi.nlm.nih.gov/pubmed/37513197
http://dx.doi.org/10.3390/molecules28145323
_version_ 1785081433457426432
author Szymańska, Patrycja
Luzak, Bogusława
Miłowska, Katarzyna
Golański, Jacek
author_facet Szymańska, Patrycja
Luzak, Bogusława
Miłowska, Katarzyna
Golański, Jacek
author_sort Szymańska, Patrycja
collection PubMed
description Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We investigated the effect of resolvin E1 on collagen-induced platelet aggregation, activation, and reactivity, and also platelet membrane fluidity. The ultimate and statistically significant results showed that resolvin E1 may inhibit platelet reactivity due to the reduction of collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood. Also, resolvin E1 significantly reduced P-selectin exposure on collagen-stimulated platelets. Moreover, we demonstrated that resolvin E1 can maintain platelet membrane structure (without increasing membrane fluidity). The association between platelet reactivity and membrane fluidity, including resolvin E1 and collagen receptors requires further research. However, the goal of this study was to shed light on the molecular mechanisms behind the anti-aggregative effects of resolvin E1 on platelets, which are still not fully clarified. We also indicate an innovative research direction focused on further analysis and then use of omega-3 PUFAs metabolites as antiplatelet compounds for future applications in the treatment and prevention of cardiovascular diseases.
format Online
Article
Text
id pubmed-10385542
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103855422023-07-30 The Anti-Aggregative Potential of Resolvin E1 on Human Platelets Szymańska, Patrycja Luzak, Bogusława Miłowska, Katarzyna Golański, Jacek Molecules Article Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We investigated the effect of resolvin E1 on collagen-induced platelet aggregation, activation, and reactivity, and also platelet membrane fluidity. The ultimate and statistically significant results showed that resolvin E1 may inhibit platelet reactivity due to the reduction of collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood. Also, resolvin E1 significantly reduced P-selectin exposure on collagen-stimulated platelets. Moreover, we demonstrated that resolvin E1 can maintain platelet membrane structure (without increasing membrane fluidity). The association between platelet reactivity and membrane fluidity, including resolvin E1 and collagen receptors requires further research. However, the goal of this study was to shed light on the molecular mechanisms behind the anti-aggregative effects of resolvin E1 on platelets, which are still not fully clarified. We also indicate an innovative research direction focused on further analysis and then use of omega-3 PUFAs metabolites as antiplatelet compounds for future applications in the treatment and prevention of cardiovascular diseases. MDPI 2023-07-11 /pmc/articles/PMC10385542/ /pubmed/37513197 http://dx.doi.org/10.3390/molecules28145323 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Szymańska, Patrycja
Luzak, Bogusława
Miłowska, Katarzyna
Golański, Jacek
The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
title The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
title_full The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
title_fullStr The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
title_full_unstemmed The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
title_short The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
title_sort anti-aggregative potential of resolvin e1 on human platelets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385542/
https://www.ncbi.nlm.nih.gov/pubmed/37513197
http://dx.doi.org/10.3390/molecules28145323
work_keys_str_mv AT szymanskapatrycja theantiaggregativepotentialofresolvine1onhumanplatelets
AT luzakbogusława theantiaggregativepotentialofresolvine1onhumanplatelets
AT miłowskakatarzyna theantiaggregativepotentialofresolvine1onhumanplatelets
AT golanskijacek theantiaggregativepotentialofresolvine1onhumanplatelets
AT szymanskapatrycja antiaggregativepotentialofresolvine1onhumanplatelets
AT luzakbogusława antiaggregativepotentialofresolvine1onhumanplatelets
AT miłowskakatarzyna antiaggregativepotentialofresolvine1onhumanplatelets
AT golanskijacek antiaggregativepotentialofresolvine1onhumanplatelets